Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Charikleia Gakiopoulou"'
Publikováno v:
Advances in Cancer Biology - Metastasis, Vol 6, Iss , Pp 100078- (2022)
Cutaneous Metastases, a rare clinical manifestation of great importance, arise critical differential diagnostic dilemmas among physicians, as it can easily masquerade into various forms. Besides histological confirmation, a few research has been cond
Externí odkaz:
https://doaj.org/article/7d0aed268c4b48e7bd36c1a653303d3e
Autor:
Despina Fotiou, Foteini Theodorakakou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Nikolaos Kanellias, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Asimina Papanikolaou, Charikleia Gakiopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos, Efstathios Kastritis
Publikováno v:
Leukemia & Lymphoma. :1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::12c6849f38de091226c06ed7130b97ab
https://doi.org/10.1080/10428194.2023.2197537
https://doi.org/10.1080/10428194.2023.2197537
Autor:
Despina Fotiou, Foteini Theodorakakou, Maria Gavriatopoulou, Magdalini Migkou, Panagiotis Malandrakis, Ioannis Ntanasis‐Stathopoulos, Nikolaos Kanellias, Evangelos Eleutherakis Papaiakovou, Evangelos Terpos, Asimina Papanikolaou, Charikleia Gakiopoulou, Meletios Athanasios Dimopoulos, Efstathios Kastritis
Publikováno v:
European Journal of Haematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4152238b7724f8680bf4781ede4ac734
https://doi.org/10.1111/ejh.13993
https://doi.org/10.1111/ejh.13993
Autor:
Dimitrios Alexandris, Nektarios Alevizopoulos, Leonidas Marinos, Georgios Kanellis, Charikleia Gakiopoulou
Publikováno v:
Journal of Oncology Pharmacy Practice. 29:252-257
Introduction Imatinib Mesylate (IM), a tyrosine kinase inhibitor, has been reported to cause several adverse reactions, most of them with cutaneous involvement. Non- Lichenoid IM associated skin reactions have been sufficiently- recorded. To our know
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf9fb146cbef5c15efce03c0a4963472
https://doi.org/10.1177/10781552221096846
https://doi.org/10.1177/10781552221096846
Autor:
Dimitrios Alexandris, Nektarios Alevizopoulos, Kostas Palamaris, Charikleia Gakiopoulou, Stamatios Theocharis
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
Introduction Anti-EGFR targeted anti-cancer treatment is associated with various skin adverse events. Cetuximab is often associated with acneiform papules and skin disorders. Hypertrichosis cited in face pinnae and eyelash trichomegaly are seldom des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da069e7875fd9ff7b1fdf52048f91831
https://pubmed.ncbi.nlm.nih.gov/35821579
https://pubmed.ncbi.nlm.nih.gov/35821579
Autor:
Efstathios Kastritis, Charikleia Gakiopoulou, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Ioanna Dialoupi, Evangelos Terpos, Ioannis Kostopoulos, Foteini Theodorakakou, Maria Roussou, Despina Fotiou, Anastasia Gatou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Panagiotis Malandrakis, Erasmia Psimenou, Smaragdi Marinaki, Maria Gavriatopoulou
Publikováno v:
British Journal of Haematology. 193:113-118
Treatment of the plasma cell clone in monoclonal gammopathy of renal significance (MGRS) is necessary in order to reduce toxic immunoglobulin load to the kidneys and salvage renal function. There are limited data on the use of daratumumab in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e683fa0c17a2c4a8184ff0296f320c2
https://doi.org/10.1111/bjh.17052
https://doi.org/10.1111/bjh.17052
Autor:
Argyrios Ntalianis, Ioannis Ntanasis-Stathopoulos, Charikleia Gakiopoulou, Meletios A. Dimopoulos, Asimina Papanikolaou, Evangelos Eleutherakis-Papaiakovou, Kimon Stamatelopoulos, Marylin Spyropoulou-Vlachou, Nikolaos Kanellias, Maria Gavriatopoulou, Alexandra Papathoma, Despina Fotiou, Efstathios Kastritis, Erasmia Psimenou, Magdalini Migkou, Eleni A. Karatrasoglou, Maria Roussou, Foteini Theodorakakou, Maria Irini Tselegkidi, Ioanna Dialoupi, Evangelos Terpos
Publikováno v:
Amyloid. 28:3-11
A rapid and deep haematologic response is fundamental in order to improve outcomes of patients with AL amyloidosis. We evaluated the impact of timing and depth of haematologic response at early time points (at 1 and 3 months from the start of therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::219dbdceb19af1bdbf6c88542801ed0d
https://doi.org/10.1080/13506129.2020.1798224
https://doi.org/10.1080/13506129.2020.1798224
Mineralocorticoid receptor signaling is implicated in carfilzomib-induced increase in blood pressure
Autor:
Constantinos A. Dimitriou, Nikolaos S. Thomaidis, M.A. Dimopoulos, Panagiota-Efstathia Nikolaou, Evangelos Gikas, S Lamprou, A Christodoulou, Efstathios Kastritis, Panagiotis Efentakis, Manousos Makridakis, E. Terpos, Ioanna Andreadou, I Barla, A Vlachou, Charikleia Gakiopoulou
Publikováno v:
European Heart Journal. 42
Introduction Carfilzomib (Cfz), an irreversible proteasome inhibitor, is a first line antineoplastic agent indicated for relapsed/refractory multiple myeloma, with its clinical use being hampered by cardiovascular adverse effects. Hypertension, is th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c87a8a86063882b6c9f4f16dc5b71a95
https://doi.org/10.1093/eurheartj/ehab724.3416
https://doi.org/10.1093/eurheartj/ehab724.3416
Autor:
Ioanna Dialoupi, Nikolaos Kanellias, Magdalini Migkou, Efstathios Kastritis, Kostantinos Efstathiou, Evangelos Terpos, Maria Gavriatopoulou, Sofoklis Kontogiannis, Christina Delavinia, Despina Fotiou, Erasmia Psimenou, Maria Roussou, Stavroula Giannouli, Charikleia Gakiopoulou, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou
Publikováno v:
Blood Cancer Journal
Blood Cancer Journal, Vol 10, Iss 11, Pp 1-5 (2020)
Blood Cancer Journal, Vol 10, Iss 11, Pp 1-5 (2020)
Carfilzomib (CFZ) is a non-reversible proteasome inhibitor approved for the treatment of patients with relapsed and refractory myeloma (RRMM). Its use has been associated with cardiovascular toxicity but although recently a signal of clinically signi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9755f31734b168c99583344e2341835c
https://doi.org/10.1038/s41408-020-00381-4
https://doi.org/10.1038/s41408-020-00381-4
Autor:
Ourania E. Tsitsilonis, Evangelos Terpos, Nikolaos Kanellias, Alexandra Papathoma, Ioannis Kostopoulos, Maria Gavriatopoulou, Ioannis P. Trougakos, Argyrios Ntalianis, Ioanna Dialoupi, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Pantelis Rousakis, Charikleia Gakiopoulou, Meletios A. Dimopoulos, Maria Irini Tselegkidi, Evangelos Eleutherakis-Papaioakovou, E Kastritis, Maria Roussou
Publikováno v:
Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis. 28(1)
The treatment of AL amyloidosis aims to eradicate the plasma cell clone and eliminate toxic free light chain production. Only in a minority of patients the plasma cell clone is completely eradicated; residual light chain production may still exist wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e46b32e387453e88ea1553484ffe7bdf
https://pubmed.ncbi.nlm.nih.gov/32783569
https://pubmed.ncbi.nlm.nih.gov/32783569